Valor pronóstico de la cistacina C como biomarcador en insuficiencia cardiaca crónica agudizada con función sistólica preservada y su relación con otros factores pronósticos clínicos

  1. Carrasco Sánchez, Francisco Javier
Dirigida per:
  1. Carlos Ruiz Frutos Director
  2. Emilio Pujol de la Llave Director/a

Universitat de defensa: Universidad de Huelva

Fecha de defensa: 19 de de maig de 2009

Tribunal:
  1. Manuel Montero Pérez-Barquero President/a
  2. Mariano Aguayo Canela Secretari/ària
  3. Francisco J. Martínez Marcos Vocal
  4. Juan Ignacio Pérez Calvo Vocal
  5. Oscar Aramburu Bodas Vocal
Departament:
  1. SOCIOLOGIA, TRABAJO SOCIAL Y SALUD PUBLICA

Tipus: Tesi

Teseo: 279686 DIALNET lock_openArias Montano editor

Resum

The aim of the work is to identify if serum levels of cystatin C on admission in patients with heart failure with preserved systolic function (HFPSF) who were hospitalized for worsening symptoms reveal a poor prognosis. We measured cystatin C in a prospective study of patients (n=233) with LVEF>45%. During a follow-up period of 6 months, 90 patients (42.1%) reached primary endpoint (mortality or readmission). The best cut-off level was 1.35 mg/L obtained by a ROC curve. Cystatin C>1.35 mg/L was associated with adjusted HR 3.12 (95% CI 1.84-5.29, P<0.001). Other statistically significant predictor factors in Cox multivariable regression analysis were pulmonary hypertension (HR 2.56; 95% CI 1.67-3.91, P<0.001) and atrial fibrillation (HR 1.56; 95% CI 1.00-2.44, P=0.037). All-cause mortality at 180 days was 23.4%. Kaplan-Meier survival curves showed higher mortality in patients with cystatin C above cut-off (log rank<0.0001). In conclusion, cystatin C is a strong and independent predictor of an unfavourable outcome.